Guideline for Monitoring of Clinical Trials for Cooperative Groups, CCOP Research Bases, and the Clinical Trials Support Unit (CTSU) Lore Lagrone Program.

Slides:



Advertisements
Similar presentations
Paula M. Jacobs, Ph.D. SAIC Frederick Cancer Imaging Program/DCTD/NCI/NIH September 5, 2006 Phase 0 Trials in Oncologic Drug Development DCTD Phase 0 Workshop.
Advertisements

AUDIT PROGRAM Tammy Neseth NCCTG Compliance Coordinator.
Nursing Research Opportunities in the USPHS CAPT. Victoria L. Anderson, RN, CRNP, MSN.
Quality Management within the Clinical Research Process
Common Mistakes & Audits 05/21/2014. Summary of audit findings by category.
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
Clinical QA Data Audits A GCP Point of View Linda Del Paggio GCP Compliance BioBridges, LLC.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
5/2010 Focused Monitoring Stakeholders May /2010 Purpose: Massachusetts Monitoring System  Monitor and evaluate program compliance with federal.
 The National Cancer Institute (NCI) is:  The largest of the Institutes that constitute the National Institutes of Health  The largest sponsor of research.
POST APPROVAL MONITORING AND EDUCATION PROGRAM Jane Lehmbeck 1, Sarah Blackman 1, Karen Davenport 2, Karen Parks 1 Office of the Vice President for Research.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
ROLE OF NURSES IN CLINICAL RESEARCH IN MALAWI OWEN DAIRE BSCN MPH RNM.
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
YALE MASTER SLIDE HERE Clinical Research Management – Is not just a handshake deal? Jamie Caldwell, MBA Director Office of Research Services for the Health.
Cancer Clinical Trials:
Cancer Clinical Trials: The Basics. 2 What Are Cancer Clinical Trials? Research studies involving people Try to answer scientific questions and find better.
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
Eligibility: The deciding factor. Eligibility Criteria Select subjects that are as homogenous as possible Select subjects that are as homogenous as possible.
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.
ACRIN Research Associates Educational Session Radiation Therapy Oncology Group Research Associates Committee Joyce Neading, RHIT, CTR Program Director,
Auditing & Quality Assurance Igor Espinoza-Delgado, M.D. Gary Smith M.Sc. Cancer Therapy Evaluation Program.
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
Building Quality Assurance into Clinical Trials. Objectives for Today: Define Quality in Research Describe How to Initiate Corrective and Preventative.
Module J Audits and Inspections Patricia E. Koziol 1Module J Final Version 1-May-2010.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Role of the Oncology Research Team Carmen B. Jacobs, RN, OCN, CCRP.
Device Clinical Trials and More… Michael E. Marcarelli, PharmD Director, Division of Bioresearch Monitoring Office of Compliance Center for Devices and.
Common Audit Findings UTHSC Institutional Review Board (IRB)
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients.
Research: Intramural and Extramural Jacquelyn Goldberg, JD CIRB Review Board Administrator Clinical Investigations Branch, CTEP Division of Cancer Treatment.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
H I P A A T R A I N I N G Self Directed Module 7 Research Disclosures For Data Custodians START Click to begin…
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
Overview of Gene Therapy Surveillance Inspections Joseph P Salewski, Chief Bioresearch Monitoring Branch CBER.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.
Research Orientation to SCCA. What is the SCCA? The SCCA brings together the outstanding adult and pediatric oncology patient care services of three world-
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Site Monitoring Shirley Frederiksen Donna Harsh.
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
CTMB Guidelines (Rev. October 2006) Section 5: Conducting the Quality Assurance Audit.
Office of Human Research Protection Georgia Health Sciences University.
CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch
Sponsor Visits and Monitoring
The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.
NCCCP Pilot – Clinical Trials Ann O’Mara, PhD, RN, FAAN Program Director Community Clinical Oncology Program Division of Cancer Prevention June 26, 2007.
ACRIN CV Committee ACRIN PDRC ACRIN PA 4008 Protocol and Regulatory Requirements Patricia Atkinson, Quality Control Monitor.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Marianne M. Elliott Office of Research Integrity and Ethics Bureau of Medicine and Surgery U. S Navy.
EXCEPTION FROM INFORMED CONSENT IN CPR DEVICE TRIALS: PROTECTION OF PATIENTS’ RIGHTS Circulatory System Devices Panel Meeting September 21, 2004 Elisa.
1 MARCH 2012 Regulatory Documents & the CTSU.
11 Radiation Therapy Oncology Group Clinical Trials Administration Sharon Hartson Stine, Director Group Administrator.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Good Clinical Practice (GCP) and Monitoring Practices
Responsibilities of Sponsor, Investigator and Monitor
IRB reporting updates.
Bozeman Health Clinical Research
Audit Pharmacy Review Rosalyn D. Williams
NIH GCP Training Amy Jo Jenkins, Sr
Presentation transcript:

Guideline for Monitoring of Clinical Trials for Cooperative Groups, CCOP Research Bases, and the Clinical Trials Support Unit (CTSU) Lore Lagrone Program Director, General Oncology M. D. Anderson CCOP Research Base

Practitioners of clinical trials have an obligation to take appropriate steps to protect both the integrity of science and human subjects who participate in research studies Why must we have audits let alone talk about audits?

NCI Clinical Trials Quality Assurance & Monitoring As the world’s largest sponsor of clinical trials of investigational antineoplastic agents and cancer clinical trials, the NCI must ensure that research data generated under its sponsorship are of high quality, reliable and verifiable.

NCI Auditing Division of Cancer Treatment and Diagnosis (DCTD) Cancer Therapy Evaluation Program (CTEP) Clinical Trials Monitoring Branch (CTMB)

Purpose of Auditing Document the accuracy of data submitted to the Cooperative Groups/Research Bases Verify investigator compliance with protocol and regulatory requirements Provide and opportunity for the audit team to share information with the institution staff concerning data quality, data management and all aspects of quality assurance

Audit Scheduling Main member institutions will be audited within eighteen months after entry of the first patient. For rapid accrual, the initial on-site audit should be done sooner than 18 months. All institutions (main members, affiliates, CCOPs and components) are eligible for an audit every 36 months but may be selected for audit at any time.

Components of Auditing Review of IRB Documentation and Informed Consent Content Review of Accountability of Investigational Agents and Pharmacy Operations Review of Patient Case Records

Selection of Protocols & Cases A minimum of three protocols representing studies conducted should be selected Emphasis to the following types of studies: IND, multi-modality, intergroup, designated prevention trials, those with high accrual Minimum cases equivalent to 10% of patients accrued since last audit Unannounced cases Limited review (eligibility/informed consent)

Audit Assessments Acceptable Acceptable Needs Follow-up Unacceptable

Acceptable No deficiencies identified Few lesser deficiencies identified Major deficiencies identified during the audit that were addressed and/or corrected prior to the audit for which documentation exists and no further action is required

Acceptable Needs Follow-up Any major deficiency identified during the audit but not corrected and/or addressed prior to the audit Multiple lesser deficiencies identified

Unacceptable Multiple major deficiencies identified A single major flagrant deficiency found Excessive number of lesser deficiencies identified

CTMB Guidelines ials/monitoring_coop_ccop_ctsu.htm